MedTrace Logo

Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer

NCT00004177 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2011-06-22

No results posted yet for this study

Summary

RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by therapy used to kill tumor cells.

PURPOSE: Phase I/II trial to study the effectiveness of radiolabeled monoclonal antibody plus peripheral stem cell transplantation in treating patients who have refractory or recurrent ovarian epithelial cancer.

Conditions

Interventions

BIOLOGICAL

filgrastim

as prescribed by physician

PROCEDURE

peripheral blood stem cell transplantation

1-2 weeks from treatment

RADIATION

indium In 111 monoclonal antibody MN-14

intravenous infusion over 30 min; single dose

RADIATION

yttrium Y 90 monoclonal antibody MN-14

intravenous infusion over 30 min; single dose

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Garden State Cancer Center at the Center for Molecular Medicine and Immunology

    lead OTHER

Principal Investigators

  • Jack D. Burton, MD · Garden State Cancer Center at the Center for Molecular Medicine and Immunology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-08-31
Primary Completion
2002-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004177 on ClinicalTrials.gov